1. Home
  2. CELU vs ATNM Comparison

CELU vs ATNM Comparison

Compare CELU & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELU
  • ATNM
  • Stock Information
  • Founded
  • CELU 2016
  • ATNM 2000
  • Country
  • CELU United States
  • ATNM United States
  • Employees
  • CELU N/A
  • ATNM N/A
  • Industry
  • CELU Biotechnology: Pharmaceutical Preparations
  • ATNM Biotechnology: Pharmaceutical Preparations
  • Sector
  • CELU Health Care
  • ATNM Health Care
  • Exchange
  • CELU Nasdaq
  • ATNM Nasdaq
  • Market Cap
  • CELU 56.9M
  • ATNM 50.2M
  • IPO Year
  • CELU N/A
  • ATNM N/A
  • Fundamental
  • Price
  • CELU $1.96
  • ATNM $1.41
  • Analyst Decision
  • CELU Strong Buy
  • ATNM Strong Buy
  • Analyst Count
  • CELU 1
  • ATNM 1
  • Target Price
  • CELU $6.00
  • ATNM $4.00
  • AVG Volume (30 Days)
  • CELU 69.1K
  • ATNM 212.5K
  • Earning Date
  • CELU 11-14-2025
  • ATNM 11-14-2025
  • Dividend Yield
  • CELU N/A
  • ATNM N/A
  • EPS Growth
  • CELU N/A
  • ATNM N/A
  • EPS
  • CELU N/A
  • ATNM N/A
  • Revenue
  • CELU $40,578,000.00
  • ATNM $90,000.00
  • Revenue This Year
  • CELU N/A
  • ATNM N/A
  • Revenue Next Year
  • CELU $76.00
  • ATNM N/A
  • P/E Ratio
  • CELU N/A
  • ATNM N/A
  • Revenue Growth
  • CELU N/A
  • ATNM 11.11
  • 52 Week Low
  • CELU $1.00
  • ATNM $1.03
  • 52 Week High
  • CELU $4.35
  • ATNM $2.41
  • Technical
  • Relative Strength Index (RSI)
  • CELU 57.50
  • ATNM 49.49
  • Support Level
  • CELU $1.62
  • ATNM $1.25
  • Resistance Level
  • CELU $2.29
  • ATNM $1.48
  • Average True Range (ATR)
  • CELU 0.15
  • ATNM 0.10
  • MACD
  • CELU 0.06
  • ATNM 0.02
  • Stochastic Oscillator
  • CELU 63.29
  • ATNM 42.70

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: